What Урокард Treats: Main Uses and Benefits

The primary therapeutic role of Урокард (Doxazosin) is applied across therapeutic domains involving chronic high blood pressure and symptoms related to functional stress in the lower urinary tract. The medication is utilized for the sustained management of chronic high blood pressure and the symptomatic relief of lower urinary tract issues.

The treatment is commonly used for managing essential or sustained hypertension and for providing relief of the signs and symptoms of Benign Prostatic Hyperplasia (BPH). This dual therapeutic effect may be part of symptomatic management in situations where patients experience both conditions, providing supportive relief when symptoms interfere with routine activities. The functional stress that the medicine addresses includes obstructive symptoms like a weak urinary stream and irritative symptoms such as nocturia (waking up to urinate).

“Relief in this domain supports symptomatic relief by assisting with maintaining functional stability and reducing daily functional interference.”

The stable reduction in blood pressure generally helps relieve the cardiovascular system and contributes to easing the overall systemic burden caused by high pressure. For BPH, the functional improvement supports improved day-to-day comfort during symptomatic periods.

Quick Fact: Relief for Disruptive Symptoms
Primary Condition Axes	Hypertension and Benign Prostatic Hyperplasia (BPH)
Symptom Domains Addressed	Elevated systemic vascular resistance and Lower Urinary Tract Symptoms (LUTS)
Patient-Oriented Benefit	Is used for managing stable blood pressure and helps ease difficulties associated with urine outflow and frequency

Regulatory References

1. Doxazosin tablet official labeling

This information is derived from official government regulatory documents (e.g., FDA, EMA equivalent) for the drug class that Урокард (Urocard) is presumed to belong to, as specific government regulatory documents for a product named "Urocard" are not publicly available.

Contraindicated Populations (Must Not Use)

Contraindication Criterion	Regulatory Restriction	Age-Group
Hepatic Impairment	Moderate or severe liver dysfunction (Child-Pugh categories B and C) is a formal Contraindication.	Adults
Drug Interactions	Concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, or ritonavir) is a formal Contraindication.	Adults
Hypersensitivity	Known allergy or severe sensitivity (such as angioedema) to the active substance or any of the product's ingredients.	All

Populations with Restricted or Conditional Use

Official labeling identifies specific groups where use is restricted or requires caution, as the balance of risk and benefit is altered.

• Severe Renal Impairment: Caution is necessary in patients with severe kidney dysfunction (creatinine clearance < 30 mL/ min).
• Mild Hepatic Impairment: Caution is necessary in patients with mild liver dysfunction.
• Other Alpha-Blockers: Concomitant use with other alpha-adrenergic antagonists is not recommended.
• QT Prolongation: Caution is advised in patients with a history of congenital or acquired QT prolongation.

Age-Related Eligibility

The medicine is not indicated for use in the pediatric population (individuals under 18 years of age), meaning safety and effectiveness have not been established in this group. Use is established in adults.

Pregnancy and Lactation

This medicine is not indicated for use in women; therefore, no regulatory eligibility status for pregnancy or breastfeeding is defined in official documents.

Interactions with other medicines and products

Regulatory information documents the interaction profile of Doxazosin (Урокард) through patterns of Pharmacodynamic Reinforcement and Metabolic Clearance Pathway Modulation.

Category	Documented Interacting Substances
Antihypertensive Agents	Other alpha-blockers; Thiazide diuretics; Beta-blockers; Calcium antagonists; ACE inhibitors
Exposure-Altering Agents	Strong CYP3A4 inhibitors (increase exposure); Cimetidine (modest increase in AUC/Cmax)
Substances with Additive Effects	Phosphodiesterase-5 (PDE-5) Inhibitors (e.g., sildenafil, tadalafil, vardenafil); Alcohol
Other Interactions	Impaired Hepatic Function (affects clearance); Prolonged GI retention (affects extended-release exposure)

The co-administration of Doxazosin with other antihypertensive agents or PDE-5 inhibitors may result in an additive blood pressure-lowering effect, potentially leading to symptomatic hypotension [1.1]. To mitigate this Pharmacodynamic Reinforcement, one regulatory authority advises initiating PDE-5 inhibitor treatment at the lowest dose after the patient is stable on Doxazosin, sometimes suggesting a 6-hour time interval between doses [3.2].

Regarding clearance, official labeling states that Doxazosin is primarily metabolized via the CYP3A4 enzyme. Consequently, caution is formally exercised when Doxazosin is co-administered with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin), as this may increase systemic exposure to Doxazosin [1.6]. Administration with alcohol is also documented to increase the hypotensive effects of the drug [3.4]. For patients with evidence of impaired hepatic function, caution is required because drug exposure is known to be increased in this population [1.5]. The standard release tablet may be taken with or without food, but the extended-release formulation is advised to be taken with breakfast [3.3, 2.5].

Selective Blockade of Alpha-1 Adrenergic Receptors

Урокард (Tamsulosin) functions as a selective competitive antagonist of the boldsymbolalphamathbf1A and boldsymbolalphamathbf1D adrenergic receptors, which are highly expressed in the smooth muscle of the prostate, prostatic capsule, and bladder neck. By occupying these receptor sites, the drug prevents the binding of endogenous catecholamines (such as norepinephrine) that are released by the sympathetic nervous system (SNS).

This binding action interrupts the Gq-protein signaling cascade. Modulation of this pathway inhibits the downstream processes that promote the increase of intracellular calcium ions ( Ca^2+) necessary for muscle contraction.

Modulating Smooth Muscle Tone in the Lower Urinary Tract

The resulting molecular blockade leads to the relaxation of the smooth muscle tissue within the prostate and surrounding urethra. This physiological action reduces the dynamic component of urethral resistance. The mechanism consists solely of a modulation of local neurogenic muscle tone, thereby facilitating the physical expansion of the urethral lumen and shaping the drug's physiological consequences.

Official Administration Protocol

Урокард (Doxazosin) is an oral medication administered once daily. The use of this drug is governed by a structured titration protocol to establish the appropriate long-term maintenance dose.

Treatment begins with a low starting dose, typically 1 mg taken once a day. This initial dose is maintained for one to two weeks before any upward adjustment is considered. Dosing is increased gradually, usually at seven to fourteen-day intervals, until the desired clinical response is achieved or the maximum dose is reached. The maximum recommended dose for the management of hypertension is generally 16 mg once daily, whereas the maximum for BPH is typically 8 mg once daily.

The administration instructions differ based on the tablet format. The standard release tablet can be taken independently of food. However, the extended-release tablet must be taken whole, swallowed intact with the morning meal, and must not be chewed, split, or crushed, as this would compromise its sustained-release mechanism.

Use in specific populations follows certain parameters: patients with hepatic impairment may require careful dose monitoring or a reduction in the standard dose. Conversely, no specific starting dose adjustment is generally required for patients with renal impairment. The entire use protocol emphasizes adherence to this gradual, low-dose-start regimen as the foundation for chronic treatment.

Research evidence / Overview of studies for Урокард (Doxazosin)

---

Evidence for Use in Benign Prostatic Hyperplasia (BPH) and LUTS

Research for Doxazosin in this context includes short-term controlled studies, such as randomized controlled trials (RCTs), where the study drug was typically compared against an inactive substance (placebo). These trials included research that examined symptom intensity or variability associated with BPH. The studies monitored patient-reported outcomes describing perceived discomfort related to LUTS, alongside objective measurements of functional urinary performance. Research explored how symptoms evolved in the observed populations, which included adult men with symptomatic BPH, regardless of whether they also had high blood pressure.

Research describes patterns observed during the study period, including measurements of standardized symptom scores. Studies monitored functional measures, such as the maximum and average urinary flow rates, over defined time intervals. These findings describe measurements related to outcomes reflecting daily functioning or activity level observed in the studies.

Evidence for Use in Essential Hypertension

Studies conducted during periods of increased physiological strain were used in research exploring how blood pressure measurements change over time. Initial research included short-term RCTs, which primarily measured changes in blood pressure readings (systolic and diastolic) over the study interval. Later research included very large-scale, long-term trials that were designed to monitor major cardiovascular outcomes, such as the occurrence of nonfatal myocardial infarction, stroke, or heart failure, when Doxazosin was used in comparison with other common antihypertensive drug classes.

Research described the changes measured during the study period concerning blood pressure readings. In the large outcome trials, the research describes the rates of serious cardiovascular events in the Doxazosin group compared to the control groups over periods of several years. Data from major outcome trials reported patterns related to blood pressure measurements; however, the study drug was also associated with an increased incidence of a specific cardiovascular outcome (heart failure) compared to a standard thiazide diuretic, when used as an initial agent in certain high-risk populations.

---

Key Evidence Gaps and Areas of Scientific Uncertainty

The core limitation remains the long-term comparative evidence. In BPH, comparative evidence is lacking, and evidence for symptom stability beyond one year is not fully established. For hypertension, findings from major outcome trials highlight that its overall long-term role in reducing cardiovascular events is an area where research provides context but not individual predictions, especially when compared to a standard diuretic. Data for certain groups, such as those with specific comorbidities or for long-term outcomes against newer drug classes, are still emerging.

Key Studies & References

1. Doxazosin for Benign Prostatic Hyperplasia: Long-Term Efficacy and Safety in Normotensive and Hypertensive Patients
2. Label: DOXAZOSIN tablet (US FDA/DailyMed)

Common questions about Урокард (FAQ)

Q: Чем Урокард отличается от других популярных лекарств для лечения проблем с мочевым пузырем?

A: According to the official product information, the active ingredient, Doxazosin, is classified as a selective Alpha-1 Adrenergic Receptor Blocker. This classification means it works by specifically relaxing the smooth muscle tissue in the prostate and surrounding lower urinary tract. The drug is also notable for its specific formulation, which includes an extended-release tablet designed to provide a sustained therapeutic concentration over a full day.

Q: Можно ли принимать Урокард, если я уже принимаю лекарства для контроля давления?

A: Regulatory documents indicate that co-administration of this medicine with other antihypertensive agents, such as beta-blockers, diuretics, or ACE inhibitors, is a documented interaction pattern. This combination may result in an additive blood pressure-lowering effect, which could potentially lead to symptomatic hypotension (low blood pressure).

Q: Почему при приеме Урокарда рекомендуется избегать грейпфрутового сока?

A: Official labeling documents state that the medicine is metabolized, or broken down, primarily via the CYP3A4 enzyme. Consequently, caution is advised when using substances that are known to strongly inhibit this enzyme, as this interaction may increase the systemic exposure to the active ingredient.

Q: Можно ли принимать Урокард, если я беременна или планирую беременность?

A: This medication is not indicated for use in women. Regulatory documents explicitly state that the safety and effectiveness for use during pregnancy or breastfeeding have not been established. This is a crucial factor to note before starting or continuing treatment.

Q: Можно ли принимать Урокард вместе с другими лекарствами от простуды или гриппа?

A: Official patient information advises consultation with a healthcare provider before taking over-the-counter cold and flu medicines. Some of these products contain ingredients that can affect blood pressure or interact with alpha-blockers. It is important to disclose all medicines, including OTC products, to your provider.

Q: Правда ли, что Урокард может помочь уменьшить частые позывы к мочеиспусканию?

A: The medicine is officially indicated for relieving lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). The drug's mechanism of muscle relaxation is the pharmacological basis used to relieve obstruction and help manage BPH symptoms, which often include a frequent need to urinate and a weak urinary stream.

Q: Через какое время после начала приема Урокарда можно ожидать какой-либо эффект?

A: For patients using the medication for BPH, symptomatic improvement has been described in clinical studies as occurring as early as one to two weeks after the start of treatment. For blood pressure management, the maximum reduction in blood pressure typically occurs approximately two to six hours after taking a dose.

Q: Обязательно ли принимать Урокард в одно и то же время каждый день?

A: Official prescribing information advises patients to take the medication once daily at the same time each day. This practice is intended to help maintain a consistent concentration of the active ingredient, which supports the drug's therapeutic goals.

Q: Существуют ли ограничения по возрасту для использования Урокарда?

A: The medicine is indicated for use only in adults. Official regulatory documents state that the safety and effectiveness have not been established for use in the pediatric population, which includes individuals under 18 years of age.

Q: Есть ли официальные данные или исследования о том, как долго можно принимать Урокард?

A: Clinical studies have examined the medicine’s use over periods of several years. Regulatory information notes that the drug’s pharmacokinetic profile is suitable for long-term treatment of essential hypertension. Furthermore, regulatory documents state that tolerance, which would decrease the drug's effectiveness over time, has not been observed during long-term use.

Q: Почему некоторые люди говорят, что Урокард не подействовал сразу?

A: This medication is typically started at a very low dose, which is then gradually increased over several weeks according to a specific protocol called titration. This slow adjustment is necessary to minimize certain side effects. For BPH, noticeable symptomatic improvement is described as occurring after at least one to two weeks, rather than immediately.

Q: Урокард – это новое лекарство или его используют уже давно?

A: The active ingredient, Doxazosin, was initially approved by regulatory authorities in 1990. This indicates that it has been used in medical practice for several decades for the management of high blood pressure and BPH symptoms.

Q: Есть ли риск развития привыкания к Урокарду?

A: The medicine is not classified as a controlled substance by regulatory bodies. Furthermore, official documents note that tolerance, where a person would need increasingly higher doses for the same effect, has not been observed during long-term treatment.

Q: Что делать, если пропустил прием Урокарда?

A: Regulatory patient information advises that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely, and the regular schedule resumed. Regulatory patient information advises against taking a double dose to compensate for a forgotten one.

Q: Есть ли специальные диетические ограничения при приеме Урокарда?

A: Official prescribing instructions advise that the extended-release tablet must be taken with the morning meal. Additionally, for patients being treated for high blood pressure, following a healthcare provider's directions for a meal plan, including a reduced salt (sodium) diet, is also advised.

Q: Что произойдет, если случайно принять две дозы Урокарда?

A: Symptoms of taking too much medicine are documented to include excessive dizziness, lightheadedness, or fainting due to low blood pressure, and an increased heart rate. Official patient information indicates that symptoms of overdosage require immediate medical attention.

Q: Может ли Урокард взаимодействовать с витаминами или пищевыми добавками?

A: Official patient information instructs patients to tell their doctor and pharmacist about all medicines they are taking. This includes prescription and over-the-counter products, as well as vitamins, herbal remedies, and nutritional supplements, to check for any potential interactions.

Q: Насколько часто встречается сухость во рту как побочный эффект Урокарда?

A: Official regulatory documents classify dry mouth as a common side effect, meaning the effect was reported in 1 to 10 out of every 100 patients in clinical studies that examined the drug.

Q: Можно ли пить кофе или алкоголь во время лечения Урокардом?

A: Official documents state that the administration of the medicine with alcohol is documented to increase the blood pressure-lowering effects of the drug. Patients should discuss alcohol consumption with their healthcare provider.

Q: Связан ли прием Урокарда с набором веса?

A: Official regulatory information lists weight increase as an uncommon side effect. This means it has been reported in less than 1 out of every 100 patients in clinical studies examining the drug’s safety profile.

Q: Урокард отпускается по рецепту или его можно купить без него?

A: The medicine is legally classified as a prescription-only medication. It is not available for purchase over the counter and requires a prescription from a licensed healthcare provider.

Q: Насколько быстро Урокард выводится из организма?

A: The medicine has a terminal plasma elimination half-life of approximately 22 hours. This long half-life is a key reason why the drug is suited for a once-daily dosing regimen.

Q: Описаны ли в официальных источниках случаи серьезных аллергических реакций на Урокард?

A: Official documents list known allergy or severe sensitivity (Hypersensitivity) to the active substance as a formal contraindication. Patient information also describes the signs of a severe allergic reaction that would require medical attention.

Q: Является ли Урокард обезболивающим средством?

A: The medicine is classified as an Alpha-1 Adrenergic Receptor Blocker and is indicated for the management of high blood pressure and symptoms of BPH. Its regulatory purpose does not include use as a pain reliever or analgesic.

Q: Можно ли прекратить прием Урокарда сразу, как только почувствовал себя лучше?

A: Official prescribing instructions advise patients to continue taking the medication unless specifically directed to stop by a healthcare provider. Official information indicates that if treatment is interrupted for a few days or longer, restarting the dosing regimen from the lowest dose is often necessary.

Q: Каковы основные компоненты, помимо действующего вещества, в составе Урокарда?

A: Regulatory documents list the active substance, Doxazosin Mesylate, and the inactive ingredients (or excipients) that make up the tablet. These inactive ingredients typically include lactose monohydrate, microcrystalline cellulose, and magnesium stearate.

Q: Почему Урокард может быть неэффективен для некоторых людей?

A: Clinical studies describe varying levels of response among the patient populations examined, and the medicine’s efficacy describes general patterns. It is known that individual physiological responses to the treatment may vary, meaning it may not work equally for everyone.

Q: Нужно ли корректировать дозу Урокарда при почечной недостаточности?

A: Official documents state that the pharmacokinetics (how the body handles the drug) remain unchanged in patients with renal impairment. Therefore, no specific starting dose adjustment is generally required for patients with kidney problems.

Q: Есть ли исследования, подтверждающие эффективность Урокарда у подростков?

A: The medicine is not indicated for the pediatric population (individuals under 18 years of age). This means that its safety and effectiveness in the treatment of teenagers have not been formally established in the official regulatory documents.

Q: Влияет ли Урокард на сексуальную функцию?

A: Official safety information lists certain documented effects on the reproductive system. Impotence is classified as an uncommon side effect. Priapism (a painful, prolonged erection) is classified as a rare or very rare event.

Q: Описывается ли Урокард как средство для лечения ночного недержания?

A: The medicine is indicated for relieving lower urinary tract symptoms (LUTS) associated with BPH, which can include symptoms of frequent urination. Nocturia, or waking up at night to urinate, is a symptom sometimes referenced in clinical trial data.

Q: Если у меня сахарный диабет, могу ли я принимать Урокард?

A: Official regulatory information notes that this medicine has been studied in patients with coexisting diabetes mellitus. It is described as being suitable for use in this population.

Q: Есть ли известное 'пиковое' время действия Урокарда после приема?

A: For the purpose of blood pressure reduction, the maximum effects of the medicine are typically observed approximately two to six hours following the administration of a dose.

Q: Какое максимальное количество времени рекомендуется принимать Урокард без перерыва?

A: The medicine’s pharmacokinetic profile supports long-term treatment of conditions like essential hypertension with a once-daily administration. Clinical studies have monitored its effects over periods of several years.

Q: Как долго могут длиться побочные эффекты Урокарда после прекращения приема?

A: Due to the medicine’s elimination rate, it may take approximately four to five days for the active ingredient to be completely cleared from the body after the treatment is stopped. This provides context for the duration during which the active ingredient may remain in the body.

Q: Содержит ли Урокард лактозу или глютен?

A: Official prescribing information confirms that the tablets contain lactose monohydrate as an inactive ingredient. The presence of gluten is not definitively stated in the official ingredient lists.

Q: Как узнать, является ли головная боль побочным эффектом Урокарда или нет?

A: Since headache is listed in official documents as a common side effect, patients are advised to discuss any bothersome symptoms with their healthcare provider. This discussion provides context on bothersome symptoms that may or may not be related to the medicine.

How to Store and Dispose of Урокард (Urocard)

Storage of Урокард (Doxazosin Mesylate) must adhere to regulatory standards to maintain product integrity.

Official Storage Conditions

The tablets must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with temporary excursions permitted up to 30 C. It is mandatory to keep the medicine in its original container, ensure it is tightly closed, and protect it from excess heat and moisture.

Child Safety and Disposal

Always store this medication out of the sight and reach of children for safety. Disposal of any unused or expired tablets and associated waste must be conducted in accordance with local and national regulations for medicinal products, and generally should not be discarded via wastewater or household trash.